https://www.selleckchem.com/pr....oducts/Raltitrexed.h
Preliminary data have suggested that metformin might potentiate cardiovascular (CV) protection by dipeptidyl peptidase-4 inhibitors (DPP-4is), but reduce CV protection by sodium-glucose cotransporter type-2 inhibitors (SGLT2is), in patients with type 2 diabetes (T2DM) at high CV-related risk. For this reason, the present meta-analyses aimed to compare metformin moderation of the CV effects of the two pharmacological classes. Major adverse CV events (3-point MACEs) were counted in high-risk patients with T2DM treated with or without
Like
Comment
Share
